Friehs I, Margossian R E, Moran A M, Cao-Danh H, Moses M A, del Nido P J
Department of Cardiac Surgery, Children's Hospital Boston, Harvard Medical School, 300 Longwood Ave., BADER 279, Boston, MA 02115, USA.
Basic Res Cardiol. 2006 May;101(3):204-13. doi: 10.1007/s00395-005-0581-0. Epub 2005 Dec 23.
Pressure-overload hypertrophy is associated with decreased capillary density in myocardium resulting in impaired substrate delivery. Treatment of hypertrophied hearts with vascular endothelial growth factor (VEGF) induces angiogenesis. Since angiogenesis is associated with extracellular matrix degradation, we sought to determine whether VEGF induced angiogenesis in hypertrophy required matrix metalloproteinases (MMP) activation.
Newborn rabbits underwent aortic banding. Progression of hypertrophy (mass-to-volume (M/V) ratio) and mid-wall contractility index was monitored by echocardiography. At 4 and 6 weeks, VEGF (2 microg/kg), vehicle or VEGF combined with GM6001 (5 mg/kg), a MMP inhibitor, was administered intrapericardially. CD-31 (indicator of angiogenesis), MMP-2, MT1-MMP and TIMPs (endogenous MMP inhibitors) expression were measured by immunoblotting. MMP-2 activity was determined by gelatin zymography.
Untreated hypertrophied hearts progressed to ventricular dilatation at 7 wks (M/V ratio: 0.75 +/- 0.07), but compensatory hypertrophy was maintained with VEGF (0.91 +/- 0.07; p < 0.05). LV contractility declined in untreated hearts from -0.41 +/- 0.9 (5 wks) to -0.73 +/- 0.5 (7 wks; p < 0.05) but remained normal with VEGF (+1.61 +/- 0.6 vs. +0.47 +/- 0.2). MMP-2 expression and activity were significantly elevated in VEGF treated hypertrophied hearts (p < 0.05) and were blocked by concomitant administration of GM6001. VEGF induced neovascularization was inhibited by addition of GM6001. MT1-MMP showed a trend to higher levels in VEGF treated hearts. TIMPs were unchanged in all three groups.
Exogenous VEGF and resultant MMP-2 activation leads to increased capillary formation in severe hypertrophy, preventing progression to ventricular dilation and dysfunction. VEGF and the associated MMP-2 activation play an important and potentially therapeutic role in vascular remodeling of hypertrophied hearts.
压力超负荷肥大与心肌毛细血管密度降低有关,导致底物输送受损。用血管内皮生长因子(VEGF)治疗肥大心脏可诱导血管生成。由于血管生成与细胞外基质降解有关,我们试图确定VEGF在肥大中诱导血管生成是否需要基质金属蛋白酶(MMP)激活。
新生兔进行主动脉缩窄。通过超声心动图监测肥大进展(质量与体积(M/V)比)和中层壁收缩性指数。在4周和6周时,将VEGF(2微克/千克)、赋形剂或VEGF与MMP抑制剂GM6001(5毫克/千克)联合心包内给药。通过免疫印迹法测量CD-31(血管生成指标)、MMP-2、MT1-MMP和TIMPs(内源性MMP抑制剂)的表达。通过明胶酶谱法测定MMP-2活性。
未经治疗的肥大心脏在7周时进展为心室扩张(M/V比:0.75±0.07),但VEGF可维持代偿性肥大(0.91±0.07;p<0.05)。未经治疗的心脏左心室收缩性从-0.41±0.9(5周)降至-0.73±0.5(7周;p<0.05),但VEGF治疗时仍保持正常(+1.61±0.6对+0.47±0.2)。VEGF治疗的肥大心脏中MMP-2表达和活性显著升高(p<0.05),并被同时给予GM6001所阻断。添加GM6001可抑制VEGF诱导的新生血管形成。MT1-MMP在VEGF治疗的心脏中呈升高趋势。三组中TIMPs均无变化。
外源性VEGF及由此产生的MMP-2激活导致严重肥大中毛细血管形成增加,防止进展为心室扩张和功能障碍。VEGF及相关的MMP-2激活在肥大心脏的血管重塑中起重要且可能具有治疗作用。